ClinicalTrials.gg
Sign In
Not yet recruitingNCT07874048CENTAURI RegisUpdated Oct 14, 2026

CENTAURI Post-Market Clinical Registry

An observational study in Paroxysmal AF, sponsored by CardioFocus. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by CardioFocus · Observational

Updated Oct 14, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this post-market clinical registry is to collect realworld clinical experience across multiple European centers regarding the safety and efficacy of the CENTAURI System

Read the detailed description

The objective of this post-market clinical registry is to collect realworld clinical experience across multiple European centers regarding the safety and efficacy of the CENTAURI System when used with three commercially available ablation catheters (i.e., Abbott TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, Boston Scientific INTELLANAV STABLEPOINT™, Biosense Webster THERMOCOOL SMARTTOUCH™) in standard clinical practice to treat adult patients with paroxysmal AF.

02

Conditions studied

  • Paroxysmal AF

Browse trials for

Keywords

  • Paroxysmal AF
  • PFA
  • Pulsed Field Ablation
03

In context

Atrial Fibrillation

3,957 studies on the registry are indexed under Atrial Fibrillation; 933 are open to participants now.

This study's planned enrollment of 300 is close to the median of 300 across 1,390 observational studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

CardioFocus is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients diagnosed with paroxysmal AF indicated for an ablation procedure according to society guidelines or participating site practice

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with paroxysmal AF and indicated for an ablation procedure according to society guidelines or participating site practice
  2. Age ≥18 years of age
  3. Patient is willing and able to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  1. Patients who have had an atriotomy within the preceding eight weeks as the recent surgery may increase the risk of perforation
  2. Patients with a prosthetic heart valve, in which the catheter may pass through, as the catheter may damage the prosthesis
  3. Patients with active systemic infection, as this may increase the risk for cardiac infection
  4. Patients with an atrial myxoma or intracardiac thrombus as the catheter could precipitate an embolus
  5. Patients with an interatrial baffle or patch as the opening could persist and produce an iatrogenic atrial shunt
  6. In patients who have vena cava embolic protection filter devices and/or known femoral thrombus who require catheter insertion from the femoral approach
  7. In patients who are hemodynamically unstable, as per physician discretion
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Interventions

  • DeviceCENTAURI System in conjunction with commercially available ablation catheters

    Pulsed Field Ablation using the CENTAURI System

06

What researchers measure

Primary outcomes

  1. Safety Outcome

    Safety will be assessed through the collection of cardiovascular related, procedure related, and/or device related adverse events (AEs) reported by the participating sites from the day of the index procedure through study exit.

    Time frame: 24 months

  2. Efficacy Outcome Acute Success

    Acute procedure success, defined as PVI of all targeted pulmonary veins using the CENTAURI System.

    Time frame: at the end of the index ablation procedure

  3. Efficacy Outcome Chronic Success

    Freedom from documented AF/AT/AFL from 61 days through 24 months of follow-up, clinically assessed by standard of care rhythm monitoring at participating sites.

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.

Of 149 industry-sponsored observational studies under Atrial Fibrillation, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 44. This study's planned 36 months is above that.

Counting every sponsor, half of 685 studies reached it within 38 months; a quarter within 22 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2026
First posted
Oct 14, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07874048
Lead sponsor
CardioFocus
Responsible party
Sponsor
First posted
Oct 14, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Vikramaditya Mediratta, MS
Contact
vmediratta@cardiofocus.com
714-717-2376
Tine Wouters
Contact
twouters@cardiofocus.com
+32 498 774371

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Atrial Fibrillation →

Other studies from this sponsor

CardioFocus

Start the discussion